This is a default text for your page '. Click above on edit this page' to modify. Be careful with the < and > signs.
You may include any references to papers as in: the use of JSmol in Proteopedia [1] or to the article describing Jmol [2] to the rescue.
2x36 is a 6 chain structure with sequence from Human. This domain belongs to the Lon protease family.
Mitochondrial Lon protease is an ATP-dependent serine protease involved in the selective degradation of abnormal proteins. LONP1 situated on chromosome 19 is the nuclear gene encoding mitochondrial Lon protein. The single species of mRNA of this protein is found in the mitochondrial matrix. This protein from human tissues has a molecular mass of 100 kDA.
Function
The mitochondrial Lon protease is an important regulator of mitochondrial metabolism including the maintenance and repair of mitochondrial DNA. This protein is also essential for homeostasis of mitochondria, and by regulating some regulatory proteins which have a short life or damaged proteins.
Lon protease has three main roles.
This protein is able to do a proteolytic digestion of oxidized proteins which allows the renewal of essential mitochondrial enzymes such as aconitase or Mitochondrial transcription factor A.
Lon protease is involved in mtDNA replication and mitogenesis by being a mitochondrial DNA-bing protein. Human Lon and mtDNA associate at the level of their at least 4 contiguous guanine sequence and form a G-quadruplex[3]. This G-rich region is the control region for mtDNA replication and transcription[4].
Mitochondrial Lon protease interacts with protein chaperone, notably HSP60-Hsp70 complex to protect cell from apoptosis under environmental stress[5].
The mitochondrial Lon protease is essentially found in the cytoplasmic of mitochondria because amino-acid has a potential mitochondrial targetting presequences[6].
Lon Human protease alternates between cycles of being bound to the mitochondrial genome and being free into the mitochondrial cytoplasm where it can degrade abnormal proteins coming from damaged proteins, errors in the synthesis, or misfolded of multimeric proteins. Its inactive conformation prevents uncontrolled proteolysis.
To achieve proteolytic cleavage, the Lon protein has to form a hexamer.
Lon protease has also a role in mtDNA quality control by permits oxidative mitochondrial DNA damage. Sensitivities of H2O2-induced mtDNA damage depend on the proportion of LON[7].
Other ATP-dependent proteases are found in eukaryotic cells and organelles like 26S protease which uses ATP hydrolysis for conjugation or ubiquitin for example.
General structure
Lon proteins are grouped into two families, LonA and LonB. The human protein LonP1 is part of the LonA proteins [8]. This protein has three isoforms obtained by alternative splicing of the portion of DNA coding for this protein [9].
Globally there is a great diversity of Lon proteins, but they are all organised in an oligomeric ring structure, mostly hexameric structure with identical subunits.
Lon proteins are therefore an hexameric chambered protease complex. (This structure is similar with yeast Pim1 )
The six Lon monomers are forming three pairs of legs owned by the N-terminal domain of the protein. This structure is emerging of the protein as a trimer of dimers.
Like many proteins, Lon is a flexible peptide which has different three-dimensional conformations. The protein can therefore pass from one conformation to another by hydrolysis of ATP.
With these conformational changes, the active sites of the Lon protein are protected from the external environment in the oligomeric complex that forms the degradation chamber.
This form of degradation chamber is also found in bacteria, plants, fungi and metazoan, the similarities with bacteria are most probably due to the endosymbiotic theory.
This protein has a proteolytic and chaperone-like activity, it cannot unfold aggregated proteins, but can participate in the assembling of some complexes). These two enzymatic activities are separated on two polypeptide chains forming a complex or two separate domains on the same polypeptide chain.
The Lon protein has three main distinct domains: the first, the N-terminal domain, is specialised in substrate binding and oligomerization. The second, called the AAA+ domain (or A domain) corresponds to the fixation and hydrolysis site of the ATP. Finally, the third domain located at the C-terminal is an active serine site leading to substrate degradation. This is a proteolytic domain, called domain P.
Mammalian Lon protein only interacts with single-stranded DNA (ssDNA) but not dsDNA. There are therefore special sequences for interaction with G-rich DNA as well as RNA. In addition, the binding of a substrate to the protein stimulates the interaction with the DNA.
mtDNA binds to the Lon protein with different affinities depending on the state of the cell and the type of cell meeting the following four parameters:
- the single stranding state of mtDNA
- the bioavailability of the mtDNA binding sites
- the affinity of the protein for a given DNA sequence
- the total number of high and low affinity Lon binding sites present
Structural highlights
Evolutionary conservation
Disease
This is a sample scene created with SAT to color by Group, and another to make a transparent representation of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
- ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:https://dx.doi.org/10.1002/ijch.201300024
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
- ↑ Bota, Daniela A., and Kelvin J. A. Davies. “Mitochondrial Lon Protease in Human Disease and Aging: Including an Etiologic Classification of Lon-Related Diseases and Disorders.” Free Radical Biology & Medicine 100 (November 2016): 188–98. https://doi.org/10.1016/j.freeradbiomed.2016.06.031.
- ↑ Lu, Bin. “Mitochondrial Lon Protease and Cancer.” Advances in Experimental Medicine and Biology 1038 (2017): 173–82. https://doi.org/10.1007/978-981-10-6674-0_12.
- ↑ Bota, Daniela A., and Kelvin J. A. Davies. “Mitochondrial Lon Protease in Human Disease and Aging: Including an Etiologic Classification of Lon-Related Diseases and Disorders.” Free Radical Biology & Medicine 100 (November 2016): 188–98. https://doi.org/10.1016/j.freeradbiomed.2016.06.031.
- ↑ García-Nafría, Javier, Gabriela Ondrovičová, Elena Blagova, Vladimir M Levdikov, Jacob A Bauer, Carolyn K Suzuki, Eva Kutejová, Anthony J Wilkinson, and Keith S Wilson. “Structure of the Catalytic Domain of the Human Mitochondrial Lon Protease: Proposed Relation of Oligomer Formation and Activity.” Protein Science : A Publication of the Protein Society 19, no. 5 (May 2010): 987–99. https://doi.org/10.1002/pro.376.
- ↑ Lu, Bin. “Mitochondrial Lon Protease and Cancer.” Advances in Experimental Medicine and Biology 1038 (2017): 173–82. https://doi.org/10.1007/978-981-10-6674-0_12.
- ↑ « The N-terminal domain plays a crucial role in the structure of a full-length human mitochondrial Lon protease | Scientific Reports ». Consulté le 13 janvier 2021. https://www.nature.com/articles/srep33631.
- ↑ He, Lihong, Dongyang Luo, Fan Yang, Chunhao Li, Xuegong Zhang, Haiteng Deng, et Jing-Ren Zhang. « Multiple domains of bacterial and human Lon proteases define substrate selectivity ». Emerging Microbes & Infections 7 (17 août 2018). https://doi.org/10.1038/s41426-018-0148-4.
